Genentech's early-stage RQx deal marks third 2013 venture exit for Avalon
This article was originally published in Scrip
With the signing of a drug discovery collaboration for broad-spectrum small molecule antibiotics between RQx Pharmaceuticals and Roche's Genentech that's worth up to $111 million plus royalties, Avalon Ventures has signed its third deal this year that allows the San Diego-based venture capital firm to exit an early-stage investment.
You may also be interested in...
Genentech’s infectious diseases and immunology dealmaker speaks to Scrip about the significance of following the science when it comes to partnering.
Private Company Edition: TVM, Focus/MD Anderson and RA Capital launched new venture capital funds. Also, LianBio’s $310m crossover financing, AavantiBio’s Sarepta-backed $107m series A and Sirnaomics’ $105m series D led recent VC rounds.
Amgen had a good third quarter despite some COVID-19 impacts but did not shed any light on filing plans for two key late-stage programs nor provide any insight into Phase III asthma results for tezepelumab.